GLNS advises CPTx GmbH in connection with USD 29 million funding by a group of diverse private and public investors.
CPTx, an innovative biotech startup committed to pioneering next-generation preventative and therapeutic solutions raised USD 29 million from a diverse group of private and public investors. The funding was led by Blueyard Capital and SPRIND, with participation from Marius Nacht Group, Andrej Henkler - Leblon Capital, Bayern Kapital, and several industry veterans, including Stefan Oschmann, former CEO of Merck KGaA.
CPTx builds on 15 years of transformative research in programmable DNA nanofabrication conducted at the Technical University of Munich by CPTx’s Founder and CEO, Prof. Hendrik Dietz. This research not only advances antiviral therapy but also paves the way for broader biopharma applications beyond infectious diseases, signaling a new era of versatile therapeutic solutions.CPTx excels in large-scale DNA single strand synthesis, DNA nanostructure creation for multivalent drug display, and advanced pharmacokinetics (PK) and conjugate engineering. These capabilities underpin CPTx’s rapidly evolving pipeline, which includes a pan-influenza antiviral and two promising partnership assets.
GLNS comprehensively advised CPTx GmbH in connection with this funding with a team led by Georg Lindner (Corporate/M&A/Tax) together with Andreas Scheidle (Tax), Dr. Stefan Bührle (Corporate/M&A), Maximilian Zrenner (Corporate/M&A/Tax) and Amadeus Möser (Corporate/M&A)
Other advisors involved: SSH Rechtsanwälte (IP), Pusch Wahlig Workplace Law (Employment), LARK (Finance).